China Universal Asset Management Co., Ltd. Kinnate Biopharma Inc. Transaction History

China Universal Asset Management Co., Ltd.

$773 Million
Q1 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 21, 2024	BUY	$1.38 - $3.31 $814 - $1,952	590 Added 96.56%	1,201 $1,000
Q3 2023 Oct 30, 2023	BUY	$1.38 - $3.31 $814 - $1,952	590 Added 96.56%	1,201 $2,000
Q2 2023 May 21, 2024	BUY	$2.33 - $6.84 $30 - $88	13 Added 2.17%	611 $1,000
Q2 2023 Jul 27, 2023	BUY	$2.33 - $6.84 $30 - $88	13 Added 2.17%	611 $2,000
Q1 2023 May 21, 2024	BUY	$3.46 - $7.98 $519 - $1,197	150 Added 33.48%	598 $3,000

Q1 2023 Apr 27, 2023	BUY	$3.46 - $7.98 $519 - $1,197	150 Added 33.48%	598 $4,000
Q4 2022 May 21, 2024	BUY	$5.26 - $12.19 $2,356 - $5,461	448 New	448 $2,000
Q4 2022 Jan 31, 2023	BUY	$5.26 - $12.19 $178 - $414	34 Added 8.21%	448 $3,000
Q3 2022 Oct 21, 2022	BUY	$9.86 - $15.76 $4,082 - $6,524	414 New	414 $5,000

Others Institutions Holding KNTE

# of Institutions

Shares Held

32.9M

Call Options Held

94.7K

Put Options Held

802K

View Full List

About Kinnate Biopharma Inc.

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

More about KNTE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account